🔗 Share this article

Given that the US proceeds with sweeping revisions to its vaccine schedules, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus shots throughout the pandemic and has concentrated on potential fatalities after COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Vaccine Schedule

Health officials had intended to unveil major revisions to the childhood vaccine schedule in December, synchronizing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US out of step with a large portion of the international standard with insufficient data for improved outcomes. The planned update has been postponed until the coming year.

In place of Vinay Prasad, Dr. Høeg is scheduled to address the audience at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this year.

A New Direction at the Agency

The acting appointment could signify a strengthened alliance between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for ending specific pediatric shot schedules in the US in order to be more in line with Denmark's approach, a nation with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – typically the responsibility of Prasad, chief of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Qualifications

Høeg has no apparent experience in pharmaceutical research, regulation or leadership, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have the requisite experience” for overseeing the CDER, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in managing a large organization. She is not an expert in pharmaceutical oversight.”

Previous commissioners of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, said Janet Woodcock. “Clearly, she has not acquired the kind of background that previous people who headed the center have had.”

CDER has an vast workload at the FDA, she emphasized.

“The public just focuses on the novel medication approvals, but the off-patent medication office clears a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and more, and every single one have to be looked after,” Dr. Woodcock noted. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a significant leadership component to the job, which oversees more than 5,000 employees. “It’s a huge leadership role, if you perform it correctly,” the former official said.

Agency Reaction and Controversial Policies

In response to inquiries about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a representative stated that the “inquiries are based on flawed premises”.

“This background matches the duties of her position,” the spokesperson said, pointing to the months Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a disputed one-day therapy clearance system that reportedly concerned her preceding directors. “How are these therapies being chosen for this voucher program? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer oversight of all drugs, aside from shots.”

Public Past Work on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, history, some experts have noted. She published a analysis using unverified crowd-sourced reports to determine the incidence of myocarditis after COVID-19 immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are riskier than they are.

Among her “desired changes” for the incoming federal leadership encompassed changing regulations for novel immunizations and discontinuing “unnecessary” vaccines, she remarked post-election on a online show. At the agency, Høeg has allegedly suggested preventing teenage boys from obtaining COVID-19 vaccinations.

“She is an all-around dogmatist who starts off with her conclusions and reverse-engineers to fit the science in a very disingenuous, untruthful manner,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|